Literature DB >> 12124177

Critical role for Gab2 in transformation by BCR/ABL.

Martin Sattler1, M Golam Mohi, Yuri B Pride, Laura R Quinnan, Nicole A Malouf, Klaus Podar, Franck Gesbert, Hiromi Iwasaki, Shaoguang Li, Richard A Van Etten, Haihua Gu, James D Griffin, Benjamin G Neel.   

Abstract

The BCR/ABL oncogene causes chronic myelogenous leukemia (CML) in humans and a CML-like disease, as well as lymphoid leukemia, in mice. p210 BCR/ABL is an activated tyrosine kinase that phosphorylates itself and several cellular signaling proteins. The autophosphorylation site tyrosine 177 binds the adaptor Grb2 and helps determine the lineage and severity of BCR/ABL disease: Tyr177 mutation (BCR/ABL-Y177F) dramatically impairs myeloid leukemogenesis, while diminishing lymphoid leukemogenesis. The critical signal(s) from Tyr177 has remained unclear. We report that Tyr177 recruits the scaffolding adaptor Gab2 via a Grb2/Gab2 complex. Compared to BCR/ABL-expressing Ba/F3 cells, BCR/ABL-Y177F cells exhibit markedly reduced Gab2 tyrosine phosphorylation and association of phosphatidylinositol-3 kinase (PI3K) and Shp2 with Gab2 and BCR/ABL, and decreased PI3K/Akt and Ras/Erk activation, cell proliferation, and spontaneous migration. Remarkably, bone marrow myeloid progenitors from Gab2 (-/-) mice are resistant to transformation by BCR/ABL, whereas lymphoid transformation is diminished as a consequence of markedly increased apoptosis. BCR/ABL-evoked PI3K/Akt and Ras/Erk activation also are impaired in Gab2 (-/-) primary myeloid and lymphoid cells. Our results identify Gab2 and its associated proteins as key determinants of the lineage and severity of BCR/ABL transformation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124177     DOI: 10.1016/s1535-6108(02)00074-0

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  118 in total

1.  G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphatase.

Authors:  Muneyoshi Futami; Quan-Sheng Zhu; Zakary L Whichard; Ling Xia; Yuehai Ke; Benjamin G Neel; Gen-Sheng Feng; Seth J Corey
Journal:  Blood       Date:  2011-06-02       Impact factor: 22.113

2.  Grb2-associated binding (Gab) proteins in hematopoietic and immune cell biology.

Authors:  Tamisha Y Vaughan; Sheetal Verma; Kevin D Bunting
Journal:  Am J Blood Res       Date:  2011

3.  Critical requirement for Stat5 in a mouse model of polycythemia vera.

Authors:  Dongqing Yan; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

4.  Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor.

Authors:  H Kameda; H Ishigami; M Suzuki; T Abe; T Takeuchi
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

5.  Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Authors:  Alan Charest; Vicky Kheifets; Julie Park; Keara Lane; Kevin McMahon; Cathy L Nutt; David Housman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

Review 6.  The Gab2 in signal transduction and its potential role in the pathogenesis of Alzheimer's disease.

Authors:  Xiao-Ling Pan; Ru-Jing Ren; Gang Wang; Hui-Dong Tang; Sheng-Di Chen
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

Review 7.  Inhibition of Ras-mediated signaling pathways in CML stem cells.

Authors:  Jessika Bertacchini; Neda Ketabchi; Laura Mediani; Silvano Capitani; Sandra Marmiroli; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-10-12       Impact factor: 6.730

8.  Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein.

Authors:  Tilman Brummer; Mark Larance; Maria Teresa Herrera Abreu; Ruth J Lyons; Paul Timpson; Christoph H Emmerich; Emmy D G Fleuren; Gillian M Lehrbach; Daniel Schramek; Michael Guilhaus; David E James; Roger J Daly
Journal:  EMBO J       Date:  2008-09-03       Impact factor: 11.598

9.  Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.

Authors:  A K Samanta; S N Chakraborty; Y Wang; H Kantarjian; X Sun; J Hood; D Perrotti; R B Arlinghaus
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

Review 10.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.